Creative Biomolecules - Olaf Hordenbach-Hotline: Explosion!?!? - 500 Beiträge pro Seite

[Webfataga]

Olaf Hordenbach hat heute auf seiner Hotline den Wert vorgestellt und von einer 100%igen-Explosion des Kurses gesprochen. Sagte er am Anfang. Habe dann aufgelegt. Leider kam meine Freundin. Weis einer was er danach angedeutet hat und warum diese Aktie explodieren soll. Alleine wegen des Zusammenschlusses zu der neuen Firma kann es ja wohl nicht sein.

[Lootar]

Eine gute Art Geld zu sparen.
Super Ingo.

[skilly]

Ha Ha, der hat bestimmt im ntv text gelesen:

"Creative Biomolecules - 100 Prozent Chance"

und ist jetzt zu geizig dort anzurufen...

Wir haben dich durchschaut, Webfataga

[Webfataga]

Danke für die Infos. Habe, nachdem meine Freundin gegangen ist, nochmals angerufen und mir alles angehört. Nur verraten was er denn nun gesagt hat werde ich Euch natürlich nun nicht.! Danke

[gholzbauer]

Ooch ... bittebitte!

[skilly]

!

Dieser Beitrag wurde vom System automatisch gesperrt. Bei Fragen wenden Sie sich bitte an [e-mail]

[Ottoeugen]

@webfataga: Was bist du denn für ein kleinkarierter Wichs.. äh Wichtel. Hast du überhaupt ein Freundin? Kann
ich mir eigentlich gar nicht vorstellen, wohnst doch sicher noch bei Mama. Kannst die ja mit deinem blöden
Gequatsche vollsabbern.
Ciao ottoeugen

[biotechholder]

C U R I S Inc.

Meine Herren!

Curis, a new exciting Biotech company will be formed on July 31., by the merging of

--------------------------------------
Creative BioMolecules, Inc. (CBMI)

Ontogeny, Inc. and

Reprogenesis, Inc.



to create the regenerative medicine company of the future.


Symbol: CBMI

website:
http://www.curis.com/


-------------------------------


Curis will fight against the following dieases:





Neurological disorders: Parkinson`s and Alzheimer`s diseases, peripheral neuropathies
Dermatological disorders: skin cancer, wound healing, hair growth
Diabetes: juvenile onset diabetes and adult insulin dependent diabetes
OntoScreen(TM): developmental biology-based screening system











--------------------------------------------------------------------------------


Patent Position
Curis will contain intellectual property positions in the areas of cells, growth factors/proteins, small molecule agonists/ antagonists and tissue engineering. The combined entities will own or have rights to more than 150 issued patents and 225 pending patent applications worldwide.



--------------------------------------------------------------------------------


Collaborations
Corporate collaborations include (partial list):

Stryker Corporation
Becton Dickinson
Incyte Pharmaceuticals Inc.
Oxford Asymmetry International
Genzyme Molecular Oncology
Perkin-Elmer`s Tropix
ComGenex
Academic collaborations include (partial list):

Harvard University
Harvard Medical School
University of Michigan
Massachusetts Institute of Technology
Stanford University
University of California - San Francisco
National Institutes of Health
The Johns Hopkins University
University of Massachusetts
And numerous other American and European centers of academic excellence

--------------------------------------------------------------------------------

Finances
Financial reserves of the combined entities as of December 31, 1999 were approximately $70 million. Curis` plan is to target at least 2 years of cash and to continue exploring product and partnership opportunities.





--------------------------------------------------------------------------------


SCIENTIFIC ADVISORY BOARD of Curis:

Douglas A. Melton, Ph.D., Chair, Harvard University
Philip A. Beachy, Ph.D., Johns Hopkins University School ofMedicine
Anders Björklund, Ph.D., University of Lund
Helena Edlund, Ph.D., University of Umeå
Thomas Edlund, Ph.D., University of Umeå
Curt R. Freed, M.D., University of Colorado School of Medicine
Brigid Hogan, Ph.D., Vanderbilt University
Philip Ingham, Ph.D., University of Sheffield
Thomas M. Jessell, Ph.D., Columbia University
Andrew McMahon, Ph.D., Harvard University
Roel Nusse, Ph.D., Stanford University School of Medicine
Matthew P. Scott, Ph.D., Stanford University School of Medicine
Cliff Tabin, Ph.D., Harvard Medical School
Christopher V. E. Wright, Ph.D., Vanderbilt University


--------------------------------------------------------------------------------



I strongly suggest to participate into this exciting new company by buying into Creative BioMolecules, Inc., CBMI !



Subordinated, you find a technical-analysis-guru system, which states, that this stock (these three stock) is not only fundamentally interesting!






CREATIVE BIO (CBMI)

Date Open High Low Last Change Volume % Change
07/19/00 13.06 13.13 11.75 11.88 -0.87 340700 -6.82 %



Today`s Opinion:
32% Buy

Yesterday`s Opinion:
48% Buy

Last Week`s Opinion:
48% Buy

Last Month`s Opinion:
8% Buy



-------